X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs J.B.CHEMICALS - Comparison Results

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES J.B.CHEMICALS VENUS REMEDIES/
J.B.CHEMICALS
 
P/E (TTM) x -3.7 17.0 - View Chart
P/BV x 0.1 2.3 6.1% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   J.B.CHEMICALS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
J.B.CHEMICALS
Mar-16
VENUS REMEDIES/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs126318 39.6%   
Low Rs61200 30.6%   
Sales per share (Unadj.) Rs301.8148.0 203.9%  
Earnings per share (Unadj.) Rs-24.919.1 -130.3%  
Cash flow per share (Unadj.) Rs2.523.9 10.6%  
Dividends per share (Unadj.) Rs00.50 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs293.3128.9 227.4%  
Shares outstanding (eoy) m12.3484.82 14.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.7 17.7%   
Avg P/E ratio x-3.813.6 -27.7%  
P/CF ratio (eoy) x36.710.8 340.0%  
Price / Book Value ratio x0.32.0 15.9%  
Dividend payout %02.6 0.0%   
Avg Mkt Cap Rs m1,15421,951 5.3%   
No. of employees `0000.92.7 33.8%   
Total wages/salary Rs m3931,841 21.4%   
Avg. sales/employee Rs Th4,026.14,590.9 87.7%   
Avg. wages/employee Rs Th425.0673.4 63.1%   
Avg. net profit/employee Rs Th-331.8592.1 -56.0%   
INCOME DATA
Net Sales Rs m3,72412,551 29.7%  
Other income Rs m23542 4.2%   
Total revenues Rs m3,74713,093 28.6%   
Gross profit Rs m3952,055 19.2%  
Depreciation Rs m338412 82.0%   
Interest Rs m35496 370.2%   
Profit before tax Rs m-2752,088 -13.2%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32469 6.7%   
Profit after tax Rs m-3071,619 -19.0%  
Gross profit margin %10.616.4 64.8%  
Effective tax rate %-11.522.5 -51.1%   
Net profit margin %-8.212.9 -63.9%  
BALANCE SHEET DATA
Current assets Rs m2,6387,778 33.9%   
Current liabilities Rs m2,3054,358 52.9%   
Net working cap to sales %8.927.2 32.8%  
Current ratio x1.11.8 64.1%  
Inventory Days Days13555 247.7%  
Debtors Days Days4680 57.9%  
Net fixed assets Rs m4,8715,713 85.3%   
Share capital Rs m123170 72.8%   
"Free" reserves Rs m3,49610,547 33.1%   
Net worth Rs m3,61910,937 33.1%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50915,574 48.2%  
Interest coverage x0.222.8 1.0%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.8 61.5%   
Return on assets %0.611.0 5.7%  
Return on equity %-8.514.8 -57.3%  
Return on capital %1.620.0 7.9%  
Exports to sales %048.7 0.0%   
Imports to sales %13.97.1 195.9%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs m517889 58.1%   
Fx inflow Rs m06,169 0.0%   
Fx outflow Rs m5171,285 40.2%   
Net fx Rs m-5174,884 -10.6%   
CASH FLOW
From Operations Rs m5141,397 36.8%  
From Investments Rs m-123-320 38.4%  
From Financial Activity Rs m-387-1,196 32.4%  
Net Cashflow Rs m4-102 -4.1%  

Share Holding

Indian Promoters % 32.9 55.4 59.3%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 0.2 3.4 5.3%  
FIIs % 0.6 3.9 14.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 37.0 179.5%  
Shareholders   20,121 30,437 66.1%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   BIOCON LTD  CADILA HEALTHCARE  AUROBINDO PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Dec 17, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS